PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients

A Clinical Study to Investigate the Pharmacokinetics/Pharmacodynamics and Tolerability of DA-1229(Evogliptin) Tablet in Renal Impaired Patients

This is a clinical study to investigate the pharmacokinetics/pharmacodynamics and tolerability of DA-1229(Evogliptin) tabletin renal impaired patients.

Inclusion Criteria:

• Age between 20 and 70
• Weights between 50 and 90kg(Female : 40 and 90kg)
• Volunteer who totally understands the progress of this clinical trials, makes decision by his free will, and signed a consent form to follow the progress
• Stable results of estimated GFR in 4 months recently

Exclusion Criteria:

• Volunteer who has past or present history of any diseases following below.(liver including hepatitis virus carrier, kidney, Neurology, immunology, pulmonary, endocrine, hematooncology, cardiology, mental disorder)
• Volunteer who had drug(DPP-4 inhibitor) hypersensitivity reaction
• Volunteer who already participated in other trials in 2 months
• Volunteer who had whole blood donation in 2 months, or component blood donation in 1 months or transfusion